
Biologics and mRNA Therapies Fuel 35% Growth in Temperature-Controlled Transport
China's healthcare cold chain logistics market is surging at 35% annual growth, projected to reach RMB 200 billion by 2028, as the booming biologics and mRNA therapy sectors drive unprecedented demand for IoT-enabled, temperature-controlled transport infrastructure.
Key Points:
- 35% annual growth rate — among the fastest-growing logistics sub-sectors
- RMB 200B target by 2028 driven by biologic drugs requiring strict cold chain compliance
- IoT-enabled monitoring becoming standard for real-time temperature and location tracking
- mRNA therapies require ultra-cold storage (-70C), creating new infrastructure demand
The cold chain boom mirrors China's rapid transition from small-molecule generics to high-value biologics. As the drug pipeline shifts toward monoclonal antibodies, cell therapies, and mRNA vaccines, cold chain logistics becomes a critical bottleneck — and a major investment opportunity.
Related Reading:
- China Innovative Drug Pipeline: 14 Biotechs, 300+ Candidates
- Trump 25% Generic Drug Tariff: A $12B Wake-Up Call
Want the full analysis?
Read the complete article on China Industry Insights.
Comments
Post a Comment